Clinical progress of nanomedicine-based RNA therapies

The clinical application of nanoparticles (NPs) to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro® in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis. The emergency use authorization or approval and widespread global us...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Siyoung A., Cox, Alysia, Tung, Madelynn, Chung, Eun Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897211/
https://www.ncbi.nlm.nih.gov/pubmed/35310381
http://dx.doi.org/10.1016/j.bioactmat.2021.10.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897211/
https://www.ncbi.nlm.nih.gov/pubmed/35310381
http://dx.doi.org/10.1016/j.bioactmat.2021.10.018

Ejemplares similares